Kyntra Bio, Inc.
KYNB - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$15.1M
Close$
$10.65
179.5% upside
Current Fair Value
179.5% upsideUndervalued by 179.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $15.10 Million |
|---|---|
| Enterprise Value | $-30,122,782.00 |
| Earnings per Share | $45.37 |
| Beta | 1.08 |
| Outstanding Shares | 4,048,000 |
Return
| Return on Equity | -2249.41% |
|---|---|
| Return on Assets | 181.24% |
| Return on Invested Capital | -79.59% |
Valuation & Multiples
| P/E Ratio | 0.06 |
|---|---|
| PEG | -0.02 |
| Price to Sales | 3.81 |
| Price to Book Ratio | -1.27 |
| Enterprise Value to Revenue | -6.53 |
| Enterprise Value to EBIT | 0.58 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | -0.18 |
| Debt to Equity | -0.67 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-3.18
Consensus analyst estimateRevenue Estimate
$2.09 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-3.55
Consensus analyst estimateRevenue Estimate
$1.77 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About FibroGen Inc
34 employees
CEO: Enrique Conterno
Kyntra Bio, Inc. is a biopharmaceutical enterprise focused on the entire spectrum of therapeutic innovation, from discovering new compounds to developing and commercializing them. Leveraging profound insights into hypoxia-inducible facto...